Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

Completed · Phase 2

Conditions studied: Acne

In brief

The purpose of the study is to evaluate the efficacy of CD07223 1.5% Gel and 0.5% gel in reducing inflammatory, non-inflammatory, and total acne lesion counts after 6 weeks of twice daily applications. The study will also evaluate the safety of the study products using tolerance and adverse event data.

Key facts

Study ID

NCT01106807

Run by

Galderma R&D

People needed

73

Starts

2010-04-01

Expected to finish

2010-09-01

Last updated by the study team

2021-02-18

Who can join

Age: 18 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• subject has a clinical diagnosis of acne vulgaris with facial involvement
• the subject has at least 15 inflammatory lesions and 25 non-inflammatory lesions (excluding the nose) but no more than 2 nodules on the face

You may not qualify if…

• subject has a severe acne form or secondary acne form
• the number of inflammatory or non-inflammatory lesions on one half-face is greater than twice the number on the other half-face
• the subject has a known allergy or sensitivity to any of the components of the study products
• subject is not willing to respect wash-out periods for topical and/or systemic treatments

Where it is running

• Burke Pharmaceuticals — Hot Springs, Arkansas, United States
• Dermatology Specialist PSC — Louisville, Kentucky, United States
• Grekin Skin Institute — Warren, Michigan, United States
• TKL Research — Rochelle Park, New Jersey, United States
• Piedmont Medical Research — Winston-Salem, North Carolina, United States
• Cetero — Fargo, North Dakota, United States
• Derm Research, Inc — Austin, Texas, United States
• J & S Studies — Bryan, Texas, United States
• Education and Research Foundation, Inc — Lynchburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.